Biotechnology

Techseriesinsight > Blog > News > Biotechnology

June 16, 2025
PRNewswire
Biotechnology

Halia Therapeutics Completes First-in-Human Phase 1 Study of HT-4253, a Novel LRRK2 Inhibitor Targeting Neuroinflammation

Halia Therapeutics, Inc., a clinical-stage biopharmaceutical company redefining treatment paradigms through inflammation-targeted and resilience-driven therapies, today announced the successful completion of its first-in-human Phase 1 clinical trial evaluating HT-4253...

June 13, 2025
PRNewswire
Biotechnology

Green Fertilizer Made with Air and Plasma: NitroCapt (Sweden) wins $2M Food Planet Prize 2025 for developing low-emission fertilizers

The Curt Bergfors Foundation is honored to announce that NitroCapt was awarded the Food Planet Prize, the world’s biggest environmental award, on June 13 in Stockholm, Sweden. This recognition highlights their exceptional contributions and potential to...

June 13, 2025
PRNewswire
Biotechnology

Keymed Biosciences Announces the Latest Clinical Trial Results of CM336 Published in the New England Journal of Medicine

On June 12, Keymed Biosciences Inc. (HKEX: 02162) announced that Prof. Jun Shi’s research team from the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences (Institute of Hematology,...

June 13, 2025
PRNewswire
Biotechnology

Ratio Therapeutics Partners with Macrocyclics for Exclusive Manufacturing and Distribution of its Radiopharmaceutical Chelator Platform

Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, announced today that it entered into an agreement granting Macrocyclics Inc....

June 12, 2025
PRNewswire
Biotechnology

Sobi share new clinical data across multiple hematologic diseases at EHA 2025

Sobi® (STO: SOBI) will present data at the 30th EHA (European Haematology Association) hybrid congress, in Milan, Italy (12-15 June). The congress will feature the latest advances in the treatment of diffuse...

June 12, 2025
PRNewswire
Biotechnology

Nona Biosciences and Visterra Partner to Advance Next-Generation Biotherapeutics for Immune-Mediated and Autoimmune Diseases

Nona Biosciences, a global biotechnology company providing integrated solutions from “Idea to IND” (I to ITM), today announced a license agreement with Visterra, Inc. to advance Visterra’s next-generation biotherapeutic pipeline for immune-mediated...

June 11, 2025
PRNewswire
Biotechnology

TC BioPharm Announces Complete Response in Minimal Residual Disease (MRD) Patient

TC BioPharm (Holdings) PLC (NASDAQ: TCBP), a clinical-stage biotechnology company pioneering gamma delta T cell therapies for the treatment of cancer, today announced the first patient treated in Cohort B, presenting with detectable...

June 9, 2025
PRNewswire
Biotechnology

COLLPLANT BROADENS ITS COLLABORATION WITH STEMCELL TECHNOLOGIES

CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its plant-derived, Type I recombinant human collagen (rhCollagen) for tissue regeneration and medical...

June 9, 2025
PRNewswire
Biotechnology

Dynavax Urges Stockholders to Support Its Director Nominees at June 11 Annual Meeting

Dynavax Technologies Corporation (Nasdaq: DVAX) (“Dynavax” or the “Company”), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today issued the following statement reiterating to stockholders its recommendation to vote “FOR”...

June 2, 2025
PRNewswire
Biotechnology

Atossa Therapeutics to Present at the Jefferies Global Healthcare Conference

Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced that Dr. Steven Quay, M.D., Ph.D., President and Chief Executive Officer,...